The Federal Trade Commission has approved a motion granting Chairman Andrew Ferguson the authority to comply with President Donald Trump’s executive orders slashing DEI programs.

U.S. Federal Trade Commission Chair Andrew Ferguson gained broad authority to purge diversity, equity and inclusion (DEI) policies at the agency after Democrats, who still have the majority on the commission,

Newsweek sought email comment from the FTC and its outgoing chairwoman, Lina Khan, on Friday. The flurry of lawsuits before the change to a GOP administration underscore the tension within the FTC between pro-regulation Democrats and anti-regulation Republicans.

New FTC Chair Andrew Ferguson is closing the agency’s Office of Workplace Inclusivity and Opportunity and placing all its employees on administrative leave, the agency said Wednesday.

Donald Trump vowed to slash grocery prices as soon as he took office, yet he has barely addressed the cost of food in the whirlwind of executive orders he signed in his first week.

Employees hoped for a long-term contract as Trump prepares a crackdown on federal unions and remote work. They got a temporary one instead.

In recent decades, Republicans defined themselves as the party of free trade. Trump-era policies have challenged this position.

Returning US President Donald Trump has made the art of the deal his trademark. The immediate future looks promising for the country’s M&A activity, with proponents welcoming his refreshing pro-business approach accompanied by less regulation.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic version cost $99 for the same amount, according to the Biosimilars Council.

Much political and media attention has focused on US President Donald Trump’s threats to impose tariffs on Canadian goods. But Canada should also be concerned about the US president’s plans for big tech.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two

The series of directives issued by President Donald Trump within hours of his swearing-in was -- as expected -- unambiguous, assertive and geopolitically important.